Stock BRPAU BIG ROCK PARTNERS ACQUISITION CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Big Rock Partners Acquisition Corp. Nasdaq

Equities

BRPAU

US0894822024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NRx Pharmaceuticals, Inc. to Participate in the EF Hutton Annual Global Conference on May 15, 2024
AQ
NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data
DJ
NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results
CI
NRx Pharmaceuticals : Notice of Acceleration - Form 8-K
PU
NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
AQ
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression
CI
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
AQ
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
AQ
NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq
MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches
MT
Top Premarket Decliners
MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket
MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital
MT
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics
CI
NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100
AQ
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
CI
NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
AQ
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
CI
NRx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Transcript : NRx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Apr 01, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BRPA Stock
  4. BRPAU Stock
  5. News Big Rock Partners Acquisition Corp.